DeCure for Monocytopenia with susceptibility to infections
DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for monocytopenia with susceptibility to infections — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMonocytopenia with susceptibility to infections maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for monocytopenia with susceptibility to infections is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 1974 abstract describes the difficulty of treating bacterial infections in severely neutropenic patients and notes that platelet transfusion had already proven useful for bleeding in thrombocytopenia, raising interest in neutrophil transfusion for infection prevention or treatment in neutropenia. No trial results are given, only the rationale.
A 2016 retrospective study of 60 adult cancer patients given vinorelbine alone or vinorelbine-based combination chemotherapy reports that monocytopenia was induced in both groups. The abstract gives a p-value of 0.053 for the comparison between groups and concludes that either protocol can cause monocytic toxicity, which may increase infection risk, particularly in AIDS patients. No survival or infection rates are reported.
A 2021 case report describes a 65-year-old woman with myelodysplastic syndrome, recurrent pneumonia, and Mycobacterium kansasii infection who was diagnosed with MonoMAC syndrome (monocytopenia and mycobacterial infection) via metagenomic sequencing, revealing a GATA2 germline mutation. She received anti-nontuberculous mycobacterial therapy and improved within two weeks. The report recommends suspecting MonoMAC in MDS/AML patients with recurrent mixed infection, pancytopenia, and monocyte absence, and performing germline mutation and pathogen sequencing.
A separate 2021 retrospective cohort study of 471 Covid-19 patients (67 severe, 404 non-severe) found that severe patients had significantly lower minimum monocyte counts during follow-up (p < 0.001). Newly developing monocytopenia and persistent monocytopenia were significantly associated with severe disease (p < 0.001 and p = 0.001, respectively). Among non-surviving patients, survival time was significantly shorter in those with monocytopenia (p = 0.029). The authors suggest monocytopenia may be a marker for mortality in Covid-19.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1974 · 72 citations
Transfusion of Neutrophils as Prevention or Treatment of Infection in Patients with Neutropenia
AbstractTREATMENT of life-threatening bacterial infections in patients with severe neutropenia is extraordinarily difficult, at least as judged by any degree of long-term success. Although factors other than neutropenia often contribute to the susceptibility of such patients to infection, there is little doubt that neutropenia per se is associated with a marked increase in the frequency and severity of infection.1 Since replacement of platelets by transfusion has proved beneficial in preventing2 and treating3 bleeding in patients with thrombocytopenia, it is natural that interest has grown in the possible prevention and treatment of infection in patients with neutropenia by transfusing neutrophils. Although . . .
International Journal of Health Sciences · 2016 · 18 citations · open access
Monocytopenia : Induction by Vinorelbine, Cisplatin and Doxorubicin in Breast : Non-Small Cell Lung and Cervix Cancer Patients
AbstractBACKGROUND: The neoplasm is still a potential threat for breast, Non-Small Cell Lung (NSCL) and cervix cancer patients. Those gradually invade into other body organs, inducing complex pathological complications. Whereas, the anticancer drugs suppress the bone marrow, resulting serious hematological toxicities. Thus, the monocytic toxicity may the chance of infections, particularly in AID's patients. OBJECTIVE: We aimed this retrospective study to investigate the monocytopenia induced by vinorelbine following chemotherapy in cancer patients. PATIENTS AND METHOD: A total 60 adult cancer patients were divided into two groups; Group-1 patients received the treatment of Vinorelbine alone while group 2 patients received Vinorelbine based combination chemotherapy. RESULT: value 0.053). CONCLUSION: Monocytopenia is induced in both of the chemotherapy protocols allows the clinical oncologists and consultant physicians to select either of the chemotherapy protocol. The therapeutic efficacy should constitute the intervening consideration to treat the breast, cervix and NSCL (Non-Small Cell Lung's) cancers.
Infection and Drug Resistance · 2021 · 11 citations · open access
Diagnosing MonoMAC Syndrome in GATA2 Germline Mutated Myelodysplastic Syndrome via Next-Generation Sequencing in a Patient with Refractory and Complex Infection: Case Report and Literature Review
AbstractAbstract: Monocytopenia and mycobacterial infection (MonoMAC) syndrome is a rare disease. Herein, we reported a 65-year-old Asian woman, previously diagnosed with myelodysplastic syndrome (MDS), suffering from recurrent pneumonia, intermittent fever, fatigue, and chest tightness lasting for five months. She was ultimately diagnosed with MonoMAC syndrome with Mycobacterium kansasii ( M. kansasii ) infection and GATA2 mutation through metagenomic generation sequencing (mNGS) of peripheral blood specimen, for which she was given anti-NTM therapy. Her situation significantly improved within 2 weeks of therapy. We discussed the clinical features, genetic characteristic, and prognosis of this disorder, aiming to further elucidate this rare syndrome. For MDS/AML patient with recurrent mixed infection and pancytopenia (especially with monocyte absence), MonoMAC syndrome should be highly suspected, and germline mutation and pathogen sequencing should be performed. Keywords: monocytopenia and mycobacterial infection syndrome, MonoMAC, M. kansasii , GATA-2 germline mutation, nontuberculous mycobacteria, next-generation sequencing
Can Monocytopenia Be a New Indicator in Determining Survival in Covid-19 Disease?
AbstractBACKGROUND: Monocytes play a central role in Covid-19 infection. Monocytopenia is especially observed in patients with severe infection. In our study, we aimed to investigate the effects of monocytopenia on survival in patients presenting with the suspicion of Covid-19. METHODS: Patients diagnosed with Covid-19 who received inpatient or outpatient treatment in the pandemic clinic of Umraniye Training and Research Hospital between April 2020 and July 2020 were included in our retrospective cohort study. Patients were divided into two groups, severe and non-severe. Demographic data, laboratory parameters, those who were monocytopenic at presentation, those who developed monocytopenia during follow-up, and those with persistent monocytopenia were noted. RESULTS: The study included 471 patients with a mean age of 50.4 ± 18.2 years. Sixty-seven (14.2%) patients had severe and 404 (85.8%) had non-severe disease. The minimum value of monocytes detected during the follow-up in severe patients was significantly lower (p < 0.001). As patients were grouped into those with monocytopenia at the time of admission, those with monocytopenia developing during their follow-up, and those whose monocytopenia at admission persisted, they were compared with regards to the presence or absence of severe disease. Newly developing monocytopenia and persistent monocytopenia were significant in patients with severe disease (p < 0.001, p = 0,001 respectively). Also, among non-surviving patients, there was a significant difference in survival times in the monocytopenia group (p = 0.029). CONCLUSIONS: In our study, we found more developing and persistent monocytopenia in the severe group, and the survival time was low, especially in those with newly developing monocytopenia. The development of monocytopenia in the daily hemogram follow-up of the patients may increase the possibility of mortality, which suggests that monocytopenia may be a new marker in determining survival.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
